Optimized S-trityl-l-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models

Journal of Medicinal Chemistry

Volumn 56, Issue 5, 2013, Pages 1878-1893

  Good, James A D ^a,c   Wang, Fang ^a,d   Rath, Oliver ^a,e   Kaan, Hung Yi Kristal ^a,f   Talapatra, Sandeep K ^a,g   Podgórski, Dawid ^a,b   MacKay, Simon P ^b   Kozielski, Frank ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c UMEÅ UNIVERSITY   (Sweden)

^d INSTITUTE OF BIOPHYSICS   (China)

^e ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^f INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3 (((3 ETHYL 4 METHYLPHENYL)(DIPHENYL)METHYL)SULFANYL)PROPANOIC ACID; 2 AMINO 5 (3,4 DIMETHYLPHENYL) 5,5 DIPHENYLPENTANOIC ACID; ANTINEOPLASTIC AGENT; CYTOCHROME P450; ISPINESIB; KINESIN; PHENYL GROUP; POTASSIUM CHANNEL HERG; PROPIONIC ACID; S TRITYL LEVO CYSTEINE; SB 743921; UNCLASSIFIED DRUG; VALERIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CANCER REGRESSION; CELL ASSAY; CHEMICAL MODIFICATION; COLON CANCER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; ELECTROPHILICITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PANCREAS CANCER; PROCESS OPTIMIZATION; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BUTYLAMINES; CELL LINE, TUMOR; CHROMONES; CYSTEINE; KINESIN; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 84875204980     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3014597     Document Type: Article

References (76)

1. Rath, O.; Kozielski, F. Kinesins and cancer Nat. Rev. Cancer 2012, 12, 527-539
2. Hirokawa, N.; Noda, Y.; Tanaka, Y.; Niwa, S. Kinesin superfamily motor proteins and intracellular transport Nat. Rev. Mol. Cell Biol. 2009, 10, 682-696
3. Good, J. A. D.; Skoufias, D. A.; Kozielski, F. Elucidating the functionality of kinesins: An overview of small molecule inhibitors Semin. Cell Dev. Biol. 2011, 22, 935-945
4. Sawin, K. E.; LeGuellec, K.; Philippe, M.; Mitchison, T. J. Mitotic spindle organization by a plus-end-directed microtubule motor Nature 1992, 359, 540-543
5. Blangy, A.; Lane, H. A.; d'Hérin, P.; Harper, M.; Kress, M.; Nigg, E. A. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo Cell 1995, 83, 1159-1169
6. Mayer, T. U.; Kapoor, T. M.; Haggarty, S. J.; King, R. W.; Schreiber, S. L.; Mitchison, T. J. Small Molecule Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based Screen Science 1999, 286, 971-974
7. Carol, H.; Lock, R.; Houghton, P. J.; Morton, C. L.; Kolb, E. A.; Gorlick, R.; Reynolds, C. P.; Maris, J. M.; Keir, S. T.; Billups, C. A.; Smith, M. A. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program Pediatr. Blood Cancer 2009, 53, 1255-1263
8. Woessner, R.; Tunquist, B.; Lemieux, C.; Chlipala, E.; Jackinsky, S.; Dewolf, W.; Voegtli, W.; Cox, A.; Rana, S.; Lee, P.; Walker, D. ARRY-520, a Novel KSP Inhibitor with Potent Activity in Hematological and Taxane-resistant Tumor Models Anticancer Res. 2009, 29, 4373-4380
9. Jackson, J. R.; Gilmartin, A.; Dhanak, D.; Knight, S.; Parrish, C.; Luo, L.; Sutton, D.; Caulder, E.; Diamond, M.; Giardiniere, M.; Zhang, S.; Huang, P.; Bergnes, G.; McDonald, A.; Lee, Y.; Sakowicz, R.; Wood, K. W. A second generation KSP inhibitor, SB-743921, is a highly potent and active therapeutic in preclinical models of cancer AACR Meeting Abstracts 2006, 2006, B11
10. Knight, S. D.; Parrish, C. A. Recent Progress in the Identification and Clinical Evaluation of Inhibitors of the Mitotic Kinesin KSP Curr. Topics Med. Chem. 2008, 8, 888-904 (Pubitemid 351984711)
11. Huszar, D.; Theoclitou, M.-E.; Skolnik, J.; Herbst, R. Kinesin motor proteins as targets for cancer therapy Cancer Metastasis Rev. 2009, 28, 197-208
12. Yan, Y.; Sardana, V.; Xu, B.; Homnick, C.; Halczenko, W.; Buser, C. A.; Schaber, M.; Hartman, G. D.; Huber, H. E.; Kuo, L. C. Inhibition of a Mitotic Motor Protein: Where, How, and Conformational Consequences J. Mol. Biol. 2004, 335, 547-554 (Pubitemid 37532655)
13. Turner, J.; Anderson, R.; Guo, J.; Beraud, C.; Fletterick, R.; Sakowicz, R. Crystal Structure of the Mitotic Spindle Kinesin Eg5 Reveals a Novel Conformation of the Neck-linker J. Biol. Chem. 2001, 276, 25496-25502
14. O'Connor, O. A.; Gerecitano, J.; Van Deventer, H.; Afanasyev, B.; Hainsworth, J.; Chen, M.; Saikali, K.; Seroogy, J.; Escandon, R.; Wolff, A.; Conlan, M. G. A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin (NHL) or Hodgkin Lymphoma (HL) Blood 2009, 114, 667-667
15. Lonial, S.; Cohen, A.; Zonder, J. A.; Benzinger, W. I.; Kaufman, J. L.; Orlowski, R. Z.; Harvey, R. D.; Alexanian, R.; Thomas, S. K.; Weber, D.; Walker, D.; Hilder, B.; Ptazynski, A.; Shah, J. J. The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM) Blood 2011, 118, 1266-1266
16. Woessner, R.; Tunquist, B.; Cox, A.; Rana, S.; Walker, D.; Lee, P. A. Combination of the KSP Inhibitor ARRY-520 with Bortezomib or Revlimid Causes Sustained Tumor Regressions and Significantly Increased Time to Regrowth in Models of Multiple Myeloma Blood 2009, 114, 1115-1116
17. DeBonis, S.; Skoufias, D. A.; Lebeau, L.; Lopez, R.; Robin, G.; Margolis, R. L.; Wade, R. H.; Kozielski, F. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities Mol. Cancer Ther. 2004, 3, 1079-1090 (Pubitemid 39295005)
18. Skoufias, D. A.; DeBonis, S.; Saoudi, Y.; Lebeau, L.; Crevel, I.; Cross, R.; Wade, R. H.; Hackney, D.; Kozielski, F. S -Trityl- l -cysteine Is a Reversible, Tight Binding Inhibitor of the Human Kinesin Eg5 That Specifically Blocks Mitotic Progression J. Biol. Chem. 2006, 281, 17559-17569 (Pubitemid 44035555)
19. Brier, S.; Lemaire, D.; DeBonis, S.; Forest, E.; Kozielski, F. Identification of the Protein Binding Region of S -Trityl- l -cysteine, a New Potent Inhibitor of the Mitotic Kinesin Eg5 Biochemistry 2004, 43, 13072-13082 (Pubitemid 39362777)
20. Kozielski, F.; Skoufias, D. A.; Indorato, R.-L.; Saoudi, Y.; Jungblut, P. R.; Hustoft, H. K.; Strozynski, M.; Thiede, B. Proteome analysis of apoptosis signaling by S -trityl- l -cysteine, a potent reversible inhibitor of human mitotic kinesin Eg5 Proteomics 2008, 8, 289-300 (Pubitemid 351212328)
21. Zee-Cheng, K.-Y.; Cheng, C.-C. Experimental antileukemic agents. Preparation and structure-activity study of S -tritylcysteine and related compounds J. Med. Chem. 1970, 13, 414-418
22. Ding, S.; Nishizawa, K.; Kobayashi, T.; Oishi, S.; Lv, J.; Fujii, N.; Ogawa, O.; Nishiyama, H. A Potent Chemotherapeutic Strategy for Bladder Cancer: (S)-Methoxy-Trityl-L-Cystein, a Novel Eg5 Inhibitor J. Urol. 2010, 184, 1175-1181
23. Xing, N.-D.; Ding, S.-T.; Saito, R.; Nishizawa, K.; Kobayashi, T.; Inoue, T.; Oishi, S.; Fujii, N.; Lv, J.-J.; Ogawa, O.; Nishiyama, H. A potent chemotherapeutic strategy in prostate cancer: S -(methoxytrityl)- l -cysteine, a novel Eg5 inhibitor Asian J. Androl. 2011, 13, 236-241
24. DeBonis, S.; Skoufias, D. A.; Indorato, R.-L.; Liger, F.; Marquet, B.; Laggner, C.; Joseph, B.; Kozielski, F. Structure-Activity Relationship of S -Trityl- l -Cysteine Analogues as Inhibitors of the Human Mitotic Kinesin Eg5 J. Med. Chem. 2008, 51, 1115-1125 (Pubitemid 351480375)
25. Ogo, N.; Oishi, S.; Matsuno, K.; Sawada, J.-i.; Fujii, N.; Asai, A. Synthesis and biological evaluation of l -cysteine derivatives as mitotic kinesin Eg5 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 3921-3924 (Pubitemid 46920939)
26. Kaan, H. Y. K.; Weiss, J.; Menger, D.; Ulaganathan, V.; Tkocz, K.; Laggner, C.; Popowycz, F.; Joseph, B.; Kozielski, F. Structure-Activity Relationship and Multidrug Resistance Study of New S -trityl- l -Cysteine Derivatives As Inhibitors of Eg5 J. Med. Chem. 2011, 54, 1576-1586
27. Kaan, H. Y. K.; Ulaganathan, V.; Hackney, D. D.; Kozielski, F. An allosteric transition trapped in an intermediate state of a new kinesin-inhibitor complex Biochem. J. 2010, 425, 55-60
28. Kim, E. D.; Buckley, R.; Learman, S.; Richard, J.; Parke, C.; Worthylake, D. K.; Wojcik, E. J.; Walker, R. A.; Kim, S. Allosteric Drug Discrimination Is Coupled to Mechanochemical Changes in the Kinesin-5 Motor Core J. Biol. Chem. 2010, 285, 18650-18661
29. Wang, F.; Good, J. A. D.; Rath, O.; Kaan, H. Y. K.; Sutcliffe, O. B.; Mackay, S. P.; Kozielski, F. Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity J. Med. Chem. 2012, 55, 1511-1525
30. Johnson, R. K.; McCabe, F. L.; Caulder, E.; Inlow-Porter, L.; Whitacre, M.; Winkler, J. D.; Bergnes, G.; Feng, B.; Morgans, D.; Wood, K. W.; Jackson, J. R. SB-715992, a potent and selective inhibitor of the mitotic kinesin KSP, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts Proc. Am. Assoc. Cancer Res. Annu. Meet. 2002, 43, 269
31. Maltese, M. Reductive Demercuration in Deprotection of Trityl Thioethers, Trityl Amines, and Trityl Ethers J. Org. Chem. 2001, 66, 7615-7625 (Pubitemid 33063953)
32. Nahm, S.; Weinreb, S. M. N -methoxy- N -methylamides as effective acylating agents Tetrahedron Lett. 1981, 22, 3815-3818
33. Kabalka, G. W.; Yao, M.-L.; Borella, S.; Goins, L. K. Iron Trichloride Mediated Allylation of Lithium Alkoxides through an Unusual Carbon-Oxygen Bond Cleavage Organometallics 2007, 26, 4112-4114 (Pubitemid 47310039)
34. Dess, D. B.; Martin, J. C. Readily accessible 12-I-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones J. Org. Chem. 1983, 48, 4155-4156
35. Yadav, J. S.; Reddy, B. V. S.; Eeshwaraiah, B.; Srinivas, M. Montmorillonite KSF clay catalyzed one-pot synthesis of α-aminonitriles Tetrahedron 2004, 60, 1767-1771 (Pubitemid 38183066)
36. Ram, S.; Spicer, L. D. Debenzylation of N -Benzylamino Derivatives by Catalytic Transfer Hydrogenation With Ammonium Formate Synth. Commun. 1987, 17, 415-418
37. Davis, F. A.; Kasu, P. V. N.; Sundarababu, G.; Qi, H. Nonracemic α-Fluoro Aldehydes: Asymmetric Synthesis of 4-Deoxy-4-fluoro- d -arabinopyranose J. Org. Chem. 1997, 62, 7546-7547 (Pubitemid 127494393)
38. Beeson, T. D.; MacMillan, D. W. C. Enantioselective Organocatalytic α-Fluorination of Aldehydes J. Am. Chem. Soc. 2005, 127, 8826-8828
39. Enders, D.; Hüttl, M. R. M. Direct Organocatalytic α-Fluorination of Aldehydes and Ketones Synlett 2005, 2005, 0991-0993
40. 3). A trifluoromethide equivalent J. Am. Chem. Soc. 1989, 111, 393-395
41. Jiang, Z.-X.; Qing, F.-L. Regioselective and Stereoselective Nucleophilic Ring Opening of Trifluoromethylated Cyclic Sulfates: Asymmetric Synthesis of Both Enantiomers of syn -(3-Trifluoromethyl)isoserine J. Org. Chem. 2004, 69, 5486-5489 (Pubitemid 39014389)
42. Shimizu, M.; Ishii, H.; Ogo, N.; Unno, Y.; Matsuno, K.; Sawada, J.-i.; Akiyama, Y.; Asai, A. S -trityl- l -cysteine derivative induces caspase-independent cell death in K562 human chronic myeloid leukemia cell line Cancer Lett. 2010, 298, 99-106
43. Carter, B. Z.; Mak, D. H.; Shi, Y.; Schober, W. D.; Wang, R.-Y.; Konopleva, M.; Koller, E.; Dean, N. M.; Andreeff, M. Regulation and Targeting of Eg5, a Mitotic Motor Protein in Blast Crisis CML: Overcoming Imatinib Resistance Cell Cycle 2006, 5, 2223-2229 (Pubitemid 44546558)
44. Cox, C. D.; Breslin, M. J.; Mariano, B. J.; Coleman, P. J.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Huber, H. E.; Kohl, N. E.; Torrent, M.; Yan, Y.; Kuo, L. C.; Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP Bioorg. Med. Chem. Lett. 2005, 15, 2041-2045 (Pubitemid 40445465)
45. Wilson, A. S.; Davis, C. D.; Williams, D. P.; Buckpitt, A. R.; Pirmohamed, M.; Park, B. K. Characterisation of the toxic metabolite(s) of naphthalene Toxicology 1996, 114, 233-242 (Pubitemid 26421936)
46. Weisberger, A. S.; Levine, B. Incorporation of Radioactive L-Cystine by Normal and Leukemic Leukocytes in Vivo Blood 1954, 9, 1082-1094
47. Goodman, L.; Ross, L. O.; Baker, B. R. Potential Anticancer Agents. V. Some Sulfur-Substituted Derivatives of Cysteine J. Org. Chem. 1958, 23, 1251-1257
48. Waring, M. J. Lipophilicity in drug discovery Expert Opin. Drug Discovery 2010, 5, 235-248
49. Abualhasan, M. N.; Good, J. A. D.; Wittayanarakul, K.; Anthony, N. G.; Berretta, G.; Rath, O.; Kozielski, F.; Sutcliffe, O. B.; Mackay, S. P. Doing the methylene shuffle-Further insights into the inhibition of mitotic kinesin Eg5 with S -trityl l -cysteine Eur. J. Med. Chem. 2012, 54, 483-498
50. Barsanti, P. A.; Wang, W.; Ni, Z.-J.; Duhl, D.; Brammeier, N.; Martin, E.; Bussiere, D.; Walter, A. O. The discovery of tetrahydro-β-carbolines as inhibitors of the kinesin Eg5 Bioorg. Med. Chem. Lett. 2010, 20, 157-160
51. Schiemann, K.; Finsinger, D.; Zenke, F.; Amendt, C.; Knöchel, T.; Bruge, D.; Buchstaller, H.-P.; Emde, U.; Stähle, W.; Anzali, S. The discovery and optimization of hexahydro-2 H -pyrano[3,2- c ]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5 Bioorg. Med. Chem. Lett. 2010, 20, 1491-1495
52. Kaan, H. Y. K.; Ulaganathan, V.; Rath, O.; Prokopcová, H.; Dallinger, D.; Kappe, C. O.; Kozielski, F. Structural Basis for Inhibition of Eg5 by Dihydropyrimidines: Stereoselectivity of Antimitotic Inhibitors Enastron, Dimethylenastron, and Fluorastrol J. Med. Chem. 2010, 53, 5676-5683
53. Nichols, D. B.; Fournet, G.; Gurukumar, K. R.; Basu, A.; Lee, J.-C.; Sakamoto, N.; Kozielski, F.; Musmuca, I.; Joseph, B.; Ragno, R.; Kaushik-Basu, N. Inhibition of hepatitis C virus NS5B polymerase by S -trityl- l -cysteine derivatives Eur. J. Med. Chem. 2012, 49, 191-199
54. Wienkers, L. C.; Heath, T. G. Predicting in vivo drug interactions from in vitro drug discovery data Nat. Rev. Drug Discovery 2005, 4, 825-833 (Pubitemid 41553963)
55. Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal Chemistry of hERG Optimizations: Highlights and Hang-Ups J. Med. Chem. 2006, 49, 5029-5046 (Pubitemid 44260200)
56. Cox, C. D.; Breslin, M. J.; Whitman, D. B.; Coleman, P. J.; Garbaccio, R. M.; Fraley, M. E.; Zrada, M. M.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Lobell, R. B.; Tao, W.; Abrams, M. T.; South, V. J.; Huber, H. E.; Kohl, N. E.; Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. Part 5: Discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β-fluorination to overcome cellular efflux by P-glycoprotein Bioorg. Med. Chem. Lett. 2007, 17, 2697-2702 (Pubitemid 46636272)
57. Zee, Y. K.; Eisen, T. Survival from lung cancer in England and Wales up to 2001 Br. J. Cancer 2008, 99, S43-S46
58. Fiebig, H. H.; Dengler, W. A.; Roth, T. Human tumor xenografts. Predictivity, characterization and discovery of new new anticancer agents. In Relevance of tumor models for anticancer drug development; Fiebig, H. H.; Burger, A. M., Eds.; Karger: Basel, 1999; Vol. 54, pp 29-50.
59. Humphries, M.; Woessner, R.; Bouhana, K.; Garrus, J.; Napier, C.; Lemieux, C.; Walker, D.; Winsk, S. Human tumor explants are better predictors of clinical trial outcome than cell line xenografts for the KSP inhibitor ARRY-520. Presented at the AACR 103rd Annual Meeting, Chicago, IL, March 31-April 4, 2012; p 1782.
60. Purcell, J. W.; Davis, J.; Reddy, M.; Martin, S.; Samayoa, K.; Vo, H.; Thomsen, K.; Bean, P.; Kuo, W. L.; Ziyad, S.; Billig, J.; Feiler, H. S.; Gray, J. W.; Wood, K. W.; Cases, S. Activity of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Models of Breast Cancer Clin. Cancer Res. 2010, 16, 566-576
61. Komlodi-Pasztor, E.; Sackett, D. L.; Fojo, A. T. Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale Clin. Cancer Res. 2012, 18, 51-63
62. Gentile, D. M.; Tomlinson, E. S.; Maggs, J. L.; Park, B. K.; Back, D. J. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation J. Pharmacol. Exp. Ther. 1996, 277, 105-112 (Pubitemid 27169049)
63. Hirashima, S.; Suzuki, T.; Ishida, T.; Noji, S.; Yata, S.; Ando, I.; Komatsu, M.; Ikeda, S.; Hashimoto, H. Benzimidazole Derivatives Bearing Substituted Biphenyls as Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase Inhibitors: Structure-Activity Relationship Studies and Identification of a Potent and Highly Selective Inhibitor JTK-109 J. Med. Chem. 2006, 49, 4721-4736 (Pubitemid 44162700)
64. Chackal-Catoen, S.; Miao, Y.; Wilson, W. D.; Wenzler, T.; Brun, R.; Boykin, D. W. Dicationic DNA-targeted antiprotozoal agents: Naphthalene replacement of benzimidazole Bioorg. Med. Chem. 2006, 14, 7434-7445 (Pubitemid 44486805)
65. Luo, L.; Carson, J. D.; Dhanak, D.; Jackson, J. R.; Huang, P. S.; Lee, Y.; Sakowicz, R.; Copeland, R. A. Mechanism of Inhibition of Human KSP by Monastrol: Insights from Kinetic Analysis and the Effect of Ionic Strength on KSP Inhibition Biochemistry 2004, 43, 15258-15266 (Pubitemid 39602187)
66. Morrison, J. F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors Biochim. Biophys. Acta, Enzymol. 1969, 185, 269-286
67. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431 (Pubitemid 38510559)
68. Powell, H. The Rossmann Fourier autoindexing algorithm in MOSFLM Acta Crystallogr., Sect. D: Biol. Crystallogr. 1999, 55, 1690-1695 (Pubitemid 29504423)
69. Evans, P. Scaling and assessment of data quality Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 72-82
70. Collaborative. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
71. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674 (Pubitemid 47080256)
72. Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L.-W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 213-221
73. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. D 2004, 60, 2126-2132 (Pubitemid 41742764)
74. Chen, V. B.; Arendall, W. B., III; Headd, J. J.; Keedy, D. A.; Immormino, R. M.; Kapral, G. J.; Murray, L. W.; Richardson, J. S.; Richardson, D. C. MolProbity: all-atom structure validation for macromolecular crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 12-21
75. Schrodinger, LLC. The PyMOL Molecular Graphics System, Version 1.3r1, 2010.
76. Cruickshank, D. Remarks about protein structure precision Acta Crystallogr., Sect. D: Biol. Crystallogr. 1999, 55, 583-601 (Pubitemid 29139232)